<DOC>
	<DOCNO>NCT00595647</DOCNO>
	<brief_summary>Prospective multicenter control randomized trial compare safety efficacy drug elute vs. bare metal stent percutaneous coronary intervention saphenous vein graft . Hypothesis : Survival outcome significantly good patient receive DES patient receive BMS regard short-term long-term outcome .</brief_summary>
	<brief_title>Study Test Efficacy Safety Drug Eluting vs. Bare-Metal Stents Saphenous Vein Graft Interventions</brief_title>
	<detailed_description>Research Question : What effect paclitaxel elute TAXUS® Liberté® stent compare bare-metal Liberté® stent ( Boston Scientific Corporation , Natick , MA ) saphenous vein graft ( SVG ) percutaneous coronary intervention ( PCI ) use conjunction glycoprotein IIb/IIIa inhibitor , e.g. , abciximab ( ReoPro® , Eli Lilly &amp; Co. , Indianapolis , IN ) , distal filter system ? Design : Prospective , multicenter , control randomize trial . Subjects : Inclusion criterion : Patients undergo SVG PCI target vessel reference diameter ≤ 5.5 mm ( visual estimate ) ; document silent ischemia , stable angina pectoris Canadian Cardiovascular Society ( CCS ) class I IV , acute coronary syndrome . Exclusion criterion : Previous stent implantation anywhere target SVG ; concomitant native vessel PCI ; SVG age &lt; 6 month ; arterial graft ; oral anticoagulation ; platelet count &lt; 100x109/L &gt; 700x109/L ; major non-cardiac condition life expectancy &lt; 12 month ; know allergy component test ; white blood cell count &lt; 3000 cell/mm3 ; enrol study ; consent ; patient unlikely comply study treatment follow-up visit . Recruitment : Consecutive sample patient qualify Variables : Predictor : Randomization single-blinded 1:1 TAXUS® Liberté® vs. Liberté® stent ( Boston Scientific Corporation , Natick , MA ) . In patient , distal filter system use PCI . The use glycoprotein IIb/IIIa inhibitor , e.g. , abciximab ( ReoPro® , Eli Lilly &amp; Co. , Indianapolis , IN ) , strongly recommend ( bolus prior PCI 12 h infusion post PCI ) . Outcome : Primary : MACE 12 month . MACE define composite cardiac death ( deaths clearly non-cardiac ) , non-fatal myocardial infarction , TVR . Secondary : Non-fatal myocardial infarction cardiac death 30 day 6 , 12 , 36 , 60 month ; MACE 30 day 6 , 36 , 60 month ; quality life ; individual component primary endpoint ; non-cardiac death ; major bleeding , define need surgery , need blood transfusion , cerebral hemorrhage antiplatelet therapy ; minor bleeding , define drop hematocrit &gt; 2 mg/dL .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients undergo SVG PCI target vessel reference diameter ≤ 5.5 mm ( visual estimate ) Documented silent ischemia , stable angina pectoris Canadian Cardiovascular Society ( CCS ) class I IV , acute coronary syndrome Previous stent implantation anywhere target SVG Concomitant native vessel PCI SVG age &lt; 6 month Arterial graft Oral anticoagulation Platelet count &lt; 100x109/L &gt; 700x109/L , white blood cell count &lt; 3000 cells/mm3 Any major noncardiac condition life expectancy &lt; 12 month Planned elective surgery next 12 month Known allergy component test Enrolled study No consent Patients unlikely comply study treatment followup visit Age &lt; 18 year Known pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>